title: Tailoring Myopic CNV Treatment Based on Preexisting Ophthalmic Condition.
authors.affiliation: Department of Medicine McGill University, Montréal, Québec, Canada 2Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada 3Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Montréal, Québec, Canada.
authors.forename: Tianwei Ellen
authors.initials: TE
authors.lastname: Zhou
authors.affiliation: Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada 3Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Montréal, Québec, Canada 4Departments of Pediatrics and Ophthalmology, Centre Hospitalier Unive.
authors.forename: Vikrant K
authors.initials: VK
authors.lastname: Bhosle
authors.affiliation: Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada 3Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Montréal, Québec, Canada 4Departments of Pediatrics and Ophthalmology, Centre Hospitalier Unive.
authors.forename: Sylvain
authors.initials: S
authors.lastname: Chemtob
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D002829:Choroid / Q000473:pathology*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D047728:Myopia, Degenerative / Q000188:drug therapy*; D000069579:Ranibizumab / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab